Skip to main content
. 2021 Sep;32(9):2375–2385. doi: 10.1681/ASN.2020121793

Table 2.

Number of events at the end of follow-up of the 4D Study stratified by quartiles of oxalate concentration at baselinea

Events Quartile 1
≤29.6 µM
n=274
Quartile 2
29.7–42.3 µM
n=279
Quartile 3
42.4–59.6 µM
n=274
Quartile 4
≥59.7 µM
n=281
All-cause mortality (n=548) 121 142 134 151
Cardiovascular eventsb (n=413) 93 97 91 132
Sudden cardiac death (n=139) 26 35 37 41
Death due to heart failure (n=38) 7 8 9 14
Myocardial infarction (n=177) 39 44 37 57
Stroke (n=90) 25 16 17 32
a

The median follow-up was 4.0 years in the atorvastatin arm and 4.1 years in the placebo arm.

b

Combined cardiovascular events were defined as a composite of death from cardiac causes, fatal or nonfatal stroke, and nonfatal myocardial infarction, whichever occurred first. Death from cardiac causes comprised death due to congestive heart failure, sudden cardiac death, fatal myocardial infarction, death due to coronary artery disease during or within 28 days after an intervention, and all other deaths attributable to coronary artery disease.